SKIN MICROBIOME Lesional area +9% vs Placebo 7% vs D0
+16% vs D0
+10% vs D0
+12% vs D0
Non-lesional area
95
D0 Placebo
D28
D0
D28 Serenibiome Figure 3: Variation in Shannon Index of lesional and non-lesional areas after 28 days S. aureus ■ S. epidemidis ■ Others ■
Lesional area -29%
vs Placebo
Non-lesional area -9%
vs Placebo
D0 Placebo
D28
D0
D28 Serenibiome
-93% S. aureus
vs D0 D0 Placebo
Bioselectively targeting Staphylococcus aureus Applied to skin health, the postbiotic glycolipid has shown exceptional and unrivaled in vitro efficacy in selectively targeting the growth of S. aureus without affecting S. epidermidis, the epidermal commensal strain. These groundbreaking results demonstrated high reproducibility and were confirmed in various experimental settings. Test conditions included monocultures of
each S. aureus and S. epidermidis strains, as well as 1:9 and 1:1 S. aureus/S. epidermidis cocultures, from both commercial and wild type bacteria, which were collected internally. Strains were suspended and diluted into a liquid culture medium of soja casein, then treated with the postbiotic glycolipid or its pure solvent ‘propanediol’, compared to a non- treated control, with each condition performed in duplicate. After 24 hours of incubation at 37°C, the
D28 D0 Figure 4: Bacterial repartition of the Staphylococci species
viable bacteria capable of forming colonies were counted using soy agar Petri dishes for commercial strains and mannitol salt agar medium for wild type. Overall, the results were consistently convincing when using either commercial or wild type strains (Table 1 and Figure 2).
Enhancing overall wellbeing and repairing the skin barrier Further studies were conducted to evaluate the capacity of this bioinspired active to reduce inflammatory and pro-inflammatory mediators. For instance, studies on human
keratinocytes cultured for 24 hours with the postbiotic glycolipid under stressed and non- stressed conditions demonstrated its ability to reduce cytokines and chemokines pro- inflammatory mediators. Another study has demonstrated the
efficacy of the postbiotic glycolipid in inducing
TABLE 1: BACTERIAL COLONIES OF STRAINS COUNTING WITH DIFFERENT TREATMENTS Bacterial colonies counting Mean total (UFC/mL)
S. aureus Control Propanediol Serenibiome
+ + + + + + + + + + + + + +
- S. epidermidis
+ + + +
+ + + + Co-culture
S. aureus : S. epidermidis + +
Mixed strains + +
S. epidermidis single strain
Mixed strains + + +
www.personalcaremagazine.com
the release of key wellbeing neuromediators, such as endorphins, which are known to increase the pain tolerance threshold and help the body to manage discomfort. This is a crucial element in targeting atopic dermatitis, a condition widely described by intense skin discomfort and a significant impact on quality of life. Preclinical studies were conducted to
evaluate the active ingredient’s ability to repair the skin barrier. An ex vivo test was performed on human skin explants treated with Serenibiome compared to a placebo. Topical application was administered
over several days, and the expression of cannabinoid receptor 2 (CB2r), responsible for reducing skin inflammation, inhibiting the nociception, and helping skin wound healing, was quantified. The results showed a +50% enhancement of CB2r expression with the postbiotic glycolipid significantly compared to the placebo. Additionally, in vitro studies demonstrated
increased keratinocytes migration, further substantiating the efficacy of the postbiotic in skin repair.
Enhancing atopic-prone skin bacterial diversity and conditions While proving efficacy through in vitro tests is important, understanding the real relationship between the host and its microbiota requires in vivo studies. Therefore, a clinical study was conducted to evaluate the capacity of the
October 2024 PERSONAL CARE D28 Serenibiome D0 Placebo D28 D0 D28 Serenibiome
-84% S. aureus
vs D0
Staphylococci (bacterial counting, reads)
Shannon index
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108
